



MEDIMAPS
We understand bone health



TBS Osteo™



TBS Osteo Next Generation

Expanded precision

Identify more patients at risk of fracture with TBS Osteo

Osteoporosis is a bone disease characterized by low bone density and deterioration of bone microarchitecture. While DXA scans measure bone density (BMD), a key factor in assessing fracture risk, they don't reveal the full picture. **Bone microarchitecture** is a critical determinant of bone strength, helping to identify more patients at risk of fracture.


Identify up to
30%
of patients at risk
of fracture¹

TBS Osteo is the only AI-ready software evaluating **bone microarchitecture** during a standard lumbar spine DXA scan thus providing the **missing link to identify more patients at high risk of fracture.**

Better Together:
DXA (bone mineral density) + TBS (bone microarchitecture)

How TBS Osteo works: bone insights within seconds

Easily installed on a DXA machine, TBS Osteo computes a patient's **Trabecular Bone Score (TBS)** which is a measure of bone texture highly correlated with bone microarchitecture.




Empowering clinicians with informed decision-making

TBS Osteo streamlines the process with an **all-in-one automatic report**. It delivers a complete picture of fracture risk to support confident, informed decision-making.

The all-in-one automatic report combines:

- **BMD**
- **Clinical risk factors or FRAX®**
- **TBS score**



1. Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res. 2011;26(11):2762-2769. doi:10.1002/jbmr.499.

Benefits



Clinical

- Identify more patients at risk of fracture by combining TBS with BMD and/or FRAX®
- Fine-tune therapy decisions and monitor changes in primary and secondary osteoporosis
- Improve patient management
- Expanded patient range covering a broader spectrum of body size phenotypes*



Workflow

- Seamlessly integrated into daily clinical workflow
- Automated and easy-to-interpret report with editable conclusions option
- No additional scan time and no additional radiation for the patient



Financial

- Increase your institution's value and reputation by attracting more referral physicians and returning patients
- Patient demand for TBS is increasing, contributing to enhanced word-of-mouth referrals
- Reimbursement available in the USA



Connectivity*

- State-of-the-art cybersecurity safeguarding hospital's network
- Secured real-time access to TBS reports everywhere
- Compatible with mobile devices and smartphones within the hospital's network
- Ensure the integrity and safety of the hospital network



Operational*

- Easy DXA fleet management
- Customizable and harmonized reporting to suit your institution's needs
- Compatible with GE and Hologic DXA models

"Assessing information related to bone microarchitecture [TBS] in addition to bone density [DXA] and clinical risk factors [FRAX] provides a more complete assessment to inform management decisions for the benefit of the patient"

Prof. Eugene McCloskey

Department of Oncology and Metabolism
at Sheffield University, UK

*Not all features are available in all countries and DXA models, for more information please contact Medimaps.

TBS used in
clinical routine
globally

>4.5M
PROCEDURES

more than 4.5 million TBS
procedures annually are
conducted worldwide

>35
GUIDELINES

TBS is recommended in
national and international
guidelines

>1500
PUBLICATIONS

in peer-reviewed medical
journals about TBS

90
COUNTRIES

in which TBS Osteo is
registered and used by the
medical community



Scan me to
book a demo
of TBS Osteo



MEDIMAPS

We understand bone health

Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management. We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment.

Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company's DNA.



swiss made software

For more information, please visit our website www.medimaps.ai © 2026 Medimaps Group. MM-BR-1250-MIG-EN-01--WW. TBS iNsight is a trademark of Medimaps Group. Not all products are available in all global markets. Please refer to your local distributor or agent. Medimaps Group reserves the right to modify the specifications and features described herein or discontinue manufacture of the product described at any time without prior notice or obligation. Please contact your authorized Medimaps representative for the most updated information. Medimaps Group is certified to ISO 13485:2016 (certificate C831121). TBS Insight is FDA 510(k) cleared and MDR compliant, CE-marked under notified body 2460.

CE 2460